Slide kit describing the results of the PFS final analysis of the ALPINE trial, a Phase 3, randomized study of zanubrutinib compared with ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).